Clinical spectrum of pyruvate kinase deficiency: data from the Pyruvate Kinase Deficiency Natural History Study.

Journal Article (Journal Article;Multicenter Study)

An international, multicenter registry was established to collect retrospective and prospective clinical data on patients with pyruvate kinase (PK) deficiency, the most common glycolytic defect causing congenital nonspherocytic hemolytic anemia. Medical history and laboratory and radiologic data were retrospectively collected at enrollment for 254 patients with molecularly confirmed PK deficiency. Perinatal complications were common, including anemia that required transfusions, hyperbilirubinemia, hydrops, and prematurity. Nearly all newborns were treated with phototherapy (93%), and many were treated with exchange transfusions (46%). Children age 5 years and younger were often transfused until splenectomy. Splenectomy (150 [59%] of 254 patients) was associated with a median increase in hemoglobin of 1.6 g/dL and a decreased transfusion burden in 90% of patients. Predictors of a response to splenectomy included higher presplenectomy hemoglobin (P = .007), lower indirect bilirubin (P = .005), and missense PKLR mutations (P = .0017). Postsplenectomy thrombosis was reported in 11% of patients. The most frequent complications included iron overload (48%) and gallstones (45%), but other complications such as aplastic crises, osteopenia/bone fragility, extramedullary hematopoiesis, postsplenectomy sepsis, pulmonary hypertension, and leg ulcers were not uncommon. Overall, 87 (34%) of 254 patients had both a splenectomy and cholecystectomy. In those who had a splenectomy without simultaneous cholecystectomy, 48% later required a cholecystectomy. Although the risk of complications increases with severity of anemia and a genotype-phenotype relationship was observed, complications were common in all patients with PK deficiency. Diagnostic testing for PK deficiency should be considered in patients with apparent congenital hemolytic anemia and close monitoring for iron overload, gallstones, and other complications is needed regardless of baseline hemoglobin. This trial was registered at as #NCT02053480.

Full Text

Duke Authors

Cited Authors

  • Grace, RF; Bianchi, P; van Beers, EJ; Eber, SW; Glader, B; Yaish, HM; Despotovic, JM; Rothman, JA; Sharma, M; McNaull, MM; Fermo, E; Lezon-Geyda, K; Morton, DH; Neufeld, EJ; Chonat, S; Kollmar, N; Knoll, CM; Kuo, K; Kwiatkowski, JL; Pospíšilová, D; Pastore, YD; Thompson, AA; Newburger, PE; Ravindranath, Y; Wang, WC; Wlodarski, MW; Wang, H; Holzhauer, S; Breakey, VR; Kunz, J; Sheth, S; Rose, MJ; Bradeen, HA; Neu, N; Guo, D; Al-Sayegh, H; London, WB; Gallagher, PG; Zanella, A; Barcellini, W

Published Date

  • May 17, 2018

Published In

Volume / Issue

  • 131 / 20

Start / End Page

  • 2183 - 2192

PubMed ID

  • 29549173

Electronic International Standard Serial Number (EISSN)

  • 1528-0020

Digital Object Identifier (DOI)

  • 10.1182/blood-2017-10-810796


  • eng

Conference Location

  • United States